NeuroVive Pharmaceutical AB—amendment number of shares and votes

STOCKHOLM--()--NeuroVive (STO:NVP):

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issues conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by an Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the Board of Directors with the authorization of a shareholders’ meeting on 31 January 2014, the number of shares and votes of NeuroVive registered with the Swedish Companies Registration Office have increased by 6,129,047. Accordingly, the total number of shares and votes in NeuroVive is 27,788,093.

About NeuroVive

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 31 March 2014, at 8:30 a.m. CET.

This information was brought to you by Cision http://news.cision.com

Contacts

For media and investor relations questions:
Ingmar Rentzhog
Laika Consulting
tel: +46 (0)46 275 62 21
or ir@neurovive.se
It is also possible to arrange an interview
with NeuroVive’s CEO Mikael Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village
SE-223 81 Lund
Sweden Tel: +46 (0)46 275 62 20 (switchboard)
Fax: + 46 (0)46 888 83 48
info@neurovive.se
www.neurovive.se

Sharing

Contacts

For media and investor relations questions:
Ingmar Rentzhog
Laika Consulting
tel: +46 (0)46 275 62 21
or ir@neurovive.se
It is also possible to arrange an interview
with NeuroVive’s CEO Mikael Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village
SE-223 81 Lund
Sweden Tel: +46 (0)46 275 62 20 (switchboard)
Fax: + 46 (0)46 888 83 48
info@neurovive.se
www.neurovive.se